Cedur - General Information:Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. [PubChem]
Other Brand Names containing Bezafibrate
Cedur - Pharmacology:
Like the other fibrates, bezafibrate is an agonist of PPARα; some studies suggest it may have some activity on PPARγ and PPARδ as well.
Cedur for patients
Data is temporarily not available
When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account:
- Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type. For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters.
- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard. This may be due to an improved glucose utilization with simultaneous reduction in insulin requirement.
- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate. Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, bezafibrate should, if necessary, be discontinued .
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired.
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
Bezafibrate must not be used in:
- liver disease (with the exception of fatty liver which is a frequent accompaniment to hypertriglyceridaemia)
- gall-bladder diseases with or without cholelithiasis (as a possible liver involvement cannot be excluded)
- Bezafibrate 200 mg: Patients with severe renal impairment presenting serum creatinine levels > 6 mg / 100 ml or creatinine clearance < 15 ml / min
- Bezafibrate retard 400 mg: in patients with renal impairment presenting serum creatinine levels > 1.5mg/100ml (>135 micromol/l) or creatinine clearance < 60 ml/min or in patients undergoing dialysis.
- known hypersensitivity to bezafibrate, to any component of the product or to other fibrates.
- known photoallergic or phototoxic reactions to fibrates
- during pregnancy and lactation
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..